Cancer Biopsy Market (2026 - 2033)

Cancer Biopsy Market Summary

The global cancer biopsy market size was valued at USD 34.8 billion in 2025 and is projected to grow from USD 37.6 billion in 2026 to USD 65.7 billion by 2033, at a CAGR of 8.3% from 2026 to 2033. The market in North America dominated with a revenue share of 41.2% in 2025. The market growth is attributed to the increasing prevalence of cancer, which is propelling the need for innovative diagnostics to provide early and effective diagnostic solutions to patients.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Moreover, the rising awareness of inherited oncology disorders and the rise in genetic testing are further anticipated to drive the growth of the cancer biopsy industry. The National Cancer Institute (NCI) 2022 update highlights that in the U.S. alone, there were approximately 20 million new cases, resulting in deaths of almost 9.7 million cancer-related deaths worldwide. These substantial figures highlight the growing cancer burden and present a significant growth opportunity for the market.

Due to the advantages of liquid biopsy technologies, massive parallel or NGS has emerged as a rapidly growing and evolving technology with increasing applications in various human Products. An increase in alterations of molecules in various types supports the usage of NGS in clinical settings, as it provides a cost- and time-effective way of detecting cancer. Tumor heterogeneity (evaluating different genes at the same time), along with the need for gene profiling, has increased the use of liquid biopsy, which is expected to propel market growth. Moreover, for various applications, such as prostate, breast, non-small-cell lung, colorectal, and ovarian cancer, liquid biopsy is used for diagnostic & screening, making it an important tool.

To learn more about this report, Download Free Sample Report

The increasing incidence of disease is propelling the demand for the diagnosis of cancers at early stages. For instance, as per Global Cancer Statistics 2024, reported by the American Cancer Society, approximately 20 million cancer cases were newly diagnosed in 2022, and 9.7 million people died from it globally. Moreover, the number of cancer cases is predicted to reach 35 million by 2050. When cancer is discovered early and is contained to the organ of origin before it has a chance to spread, survival rates drastically increase, and it is more likely to be effectively cured. Early detection is crucial for lowering cancer-related mortality, especially through efficient screening programs. Early detection increases patient survival rates by 5 to 10 times more than late detection. The 5-year cancer-specific survival rate is only 21% when cancer is discovered after it has spread, as opposed to 89% when it is found early & still localized.

Furthermore, the increasing number of initiatives by various organizations to raise awareness is a major reason for the growing demand for diagnostic products worldwide. Collaborations and partnerships undertaken by CDC, WHO, the National Cervical Cancer Coalition, the U.S. Preventive Services Task Force, & others are expected to drive market growth by increasing cervical cancer screening rates. In addition, major market players are undertaking initiatives to increase awareness about cervical, vulvar, and vaginal cancer, which is likely to encourage people to opt for screening at regular intervals.

For instance, in 2024, India, the U.S., Australia, and Japan launched the Quad Cancer Moonshot Initiative, which was specifically focused on eliminating cervical cancer across the Indo-Pacific region. Similarly, in October 2024, the University of New South Wales (UNSW) Sydney received a donation of USD 25.9 million from the Swire Group. This funding allowed the Kirby Institute at UNSW Sydney to screen 130,000 women in seven Pacific countries, including Fiji, Kiribati, the Republic of Marshall Islands, Samoa, Solomon Islands, Tonga, and Vanuatu, for cervical cancer.

Moreover, awareness among people about early diagnosis and available treatment options and advancements in treatments has substantially improved patient outcomes. According to a Cancer Progress Report published by the American Association for Cancer Research, it was expected that in the U.S., around 2,001,140 new cases of cancer would be diagnosed in 2024, and approximately 611,720 people might die from the Disease.

However, the high cost of diagnostic tests is anticipated to hamper the overall market growth. Diagnostic cancer tests are expensive, increasing the financial burden on families of patients. The government insurance framework is less well-defined in developing countries than in developed countries. Thus, the middle-class patient population who are uninsured cannot afford these tests. In addition, many private insurance players do not cover costs associated with diagnosis in developing countries. As a result, the high cost of diagnosis is limiting the adoption of screening tools, especially in developing countries. However, the scenario is expected to change in the coming years due to booming medical tourism in countries such as India and Malaysia, wherein healthcare treatments & diagnostic solutions are becoming affordable.

Market Dynamics

The cancer biopsy market is experiencing growth driven by the rising global burden of cancer, increasing adoption of precision medicine, and expanding use of molecular diagnostics in oncology care. Biopsy procedures continue to represent a fundamental component of cancer diagnosis and management by enabling disease confirmation, tumor characterization, and biomarker identification for targeted treatment selection. Growing clinical acceptance of liquid biopsy technologies is further supporting market expansion, as these approaches provide a minimally invasive method for tumor profiling and longitudinal disease monitoring. In addition, the integration of genomic profiling and advanced molecular testing into routine diagnostic workflows is enhancing the clinical value of biopsy based testing and supporting more personalized treatment strategies. Investments in advanced diagnostic pathways by healthcare systems are also improving access to precision oncology solutions. For instance, in May 2025, NHS England implemented a nationwide rollout of liquid biopsy testing for eligible lung and advanced breast cancer patients to facilitate faster identification of actionable mutations and support timely treatment selection. Such developments are accelerating the adoption of advanced biopsy technologies and contributing to the expansion of the cancer biopsy market.

Market Concentration & Characteristics

The degree of innovation is high in the cancer biopsy market, particularly in innovations such as liquid biopsy, Next-Generation Sequencing (NGS), and molecular imaging technologies. Liquid biopsy technology has emerged as a major development in the market, allowing the detection of cancer-related biomarkers from blood samples. This minimally invasive approach facilitates early detection, monitoring of treatment responses, and detection of recurrence. Companies like Guardant Health and Foundation Medicine are some of the leading players in this innovation, utilizing tests for circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes.

The merger and acquisition activities are moderate in the cancer biopsy industry, driven by strategic expansion, technological advancement, consolidation, and financial investment. Companies are actively adopting M&A to diversify their product portfolios, integrate innovative technologies, enhance market leadership, and accelerate research and development. This trend reflects the ongoing evolution of diagnostics and the growing importance of advanced biopsy solutions in improving detection and treatment.

To learn more about this report, Download Free Sample Report

Regulations largely impact the use of biopsies. However, they play a crucial role in ensuring patient safety and maintaining high-quality standards. However, they also present challenges, including increased costs, market access barriers, and variability across global markets.

In diagnosis, several alternatives to traditional biopsy procedures offer valuable options for reducing invasiveness and enhancing accuracy. Liquid biopsy is a leading alternative, analyzing biomarkers like circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from blood samples, which facilitates early cancer detection and monitoring without the need for invasive tissue sampling. Advanced imaging techniques, such as PET and MRI, provide detailed insights into tumor characteristics and can sometimes reduce the immediate need for biopsy by guiding diagnosis through non-invasive methods.

The concentration of end users in the market reflects the diversity of healthcare settings and specialties that utilize biopsy solutions for diagnosis. End users in this market typically include hospitals, diagnostic laboratories, research institutions, and specialized centers. The concentration of these end users is influenced by various factors, including the type of biopsy technology, the healthcare infrastructure in a region, and the specific needs of patients.

Analyst Perspective

The cancer biopsy market is expected to maintain a growth trajectory, driven by the increasing global cancer burden, expanding utilization of precision oncology, and growing demand for biomarker guided treatment strategies. The market is undergoing a gradual shift toward advanced molecular diagnostic approaches, with liquid biopsy gaining clinical acceptance for cancer detection, treatment monitoring, and minimal residual disease assessment. However, tissue biopsy continues to represent a fundamental component of oncology diagnostics due to its established role in disease confirmation and tumor characterization. Advancements in genomic profiling, next generation sequencing, and companion diagnostics are enhancing the clinical value of biopsy-based testing. Furthermore, ongoing investments, strategic collaborations, and product innovation initiatives are expected to support technology adoption and strengthen the long-term growth outlook of the cancer biopsy market.

Product Insights

Based on product, the kits and consumables segment led the market with the largest revenue share of 62.4% in 2025, driven by the rising adoption and usage of kits for effective screening and diagnosis solutions. Technological advancements in biopsy technologies are also contributing to market growth. Innovations such as advanced biopsy needles, specialized collection containers, and improved tissue preservation solutions are enhancing the efficiency and accuracy of biopsy procedures. Additionally, the trend toward personalized medicine, which often requires detailed molecular and genetic analysis, is increasing the need for advanced biopsy kits and consumables.

The instruments segment is expected to register the fastest CAGR of 9.5% during the forecast period. The segment's growth is expected to be driven by advancements in technology and the increasing demand for precise diagnostic tools. This growth is largely driven by the rising incidence, which accelerates the need for advanced biopsy instruments used in detecting and analyzing tumors. Innovations in biopsy technologies, such as automated tissue processors, advanced imaging systems, and precision-guided biopsy needles, are enhancing the accuracy and efficiency of cancer diagnostics. Moreover, technological advancements, including the integration of digital pathology and robotics, are further accelerating market growth.

Type Insights

Based on type, the tissue biopsies segment led the market with the largest revenue share of 61.3% in 2025, driven by increasing cancer incidence and advancements in biopsy technology. The shift towards personalized medicine, which requires detailed molecular and genetic profiling of tumors, is increasing the need for sophisticated tissue biopsy methods. The development of minimally invasive biopsy techniques also contributes to market growth by offering patients less discomfort and faster recovery times. The expansion of healthcare infrastructure and increased awareness about the importance of early detection are further boosting the demand for tissue biopsies.

The liquid biopsies segment is expected to register the fastest CAGR of 9.2% during the forecast period. Liquid biopsy is an innovative testing technology for diagnosing tumor-related genetic alterations. It has also been used to stratify tumors and provide appropriate precision oncology treatment. For instance, in January 2023, Guardant Health received FDA approval for Guardant360 CDx, its liquid biopsy assay as a companion diagnostic for the diagnosis of ESR1 mutant breast cancer. These recent advancements, expansions, and innovations in the industry promoting the use of liquid biopsy are driving the market. Due to the advantages of liquid biopsy technologies, NGS or massive parallel sequencing is the fastest-growing and evolving technology with increasing applications in various human Products. An increase in alterations of molecules in different types supports the usage of NGS in clinical settings, as it provides a cost- and time-effective way of detecting. For instance, in June 2025, Altum Sequencing developed a liquid biopsy technology, which can detect breast cancer relapse up to 6 months before symptoms become apparent through traditional diagnostic methods.

Application Insights

Based on applications, the breast cancer segment led the market with the largest revenue share of 16.8% in 2025. Increasing R&D in advanced screening tools is anticipated to boost the segment significantly. A research study published in The Institute of Cancer Research in June 2024 stated that a new type of blood test can predict breast cancer recurrence in high-risk patients, years/months before they relapse.

To learn more about this report, Download Free Sample Report

The kidney cancer segment is expected to grow at significant CAGR of 10.4% during the forecast period. An increase in research activities conducted by various players operating in the cancer biopsy industry is anticipated to boost segment growth soon. In March 2024, Elypta announced results from the international AURORAX-0087A (AUR87A) study. The study was conducted across 29 hospitals in the UK, the U.S., the EU, and Canada. It showed the possible transformative impact of a urine-based test in the monitoring of kidney cancer patients’ recurrent disease.

Regional Insights

North America dominated the Cancer Biopsy Market with the largest revenue share of 41.2% in 2025. The region's dominance is attributed to the presence of advanced healthcare infrastructure and substantial healthcare expenditure in North America, driving the widespread adoption of diagnostic technologies. In addition, several product launches and funding are further anticipated to drive market growth in the region. For instance, in February 2024, Freenome, a biotechnology company focused on developing blood tests for early detection, secured USD 254 million in funding from new and existing investors. This funding is expected to help Freenome advance its single-cancer and tailored Multicancer Early Detection (MCED).

To learn more about this report, Download Free Sample Report

U.S. Cancer Biopsy Market Trends

The Cancer Biopsy Market in the U.S. held the largest share in the North America region in 2025, due to the high cancer prevalence in the country and consequent rapid adoption of biopsies. Furthermore, rapid technological advancements, recent FDA approvals, and intense competition between companies are expected to boost market growth over the forecast period. In July 2025, NeoGenomics, Inc. announced the launch of a blood-based comprehensive genomic profiling (CGP) test, Neo PanTracer LBx. It enhances NeoGenomics' clinical portfolio and offers new revenue streams in trial matching, therapy selection, and disease monitoring.

Europe Cancer Biopsy Market Trends

The cancer biopsy industry in Europe accounted for a significant revenue share in 2025. This can be attributed to increased approvals by regulatory bodies, intense competition between companies to increase market share, a rise in government initiatives, and improved reimbursement scenarios.

The UK cancer biopsy market is growing primarily due to commercial partnerships between the government and key players for the country's routine use of cancer biopsies. For instance, in August 2025, Nonacus, an early cancer testing company, announced two West Midlands-based trials to analyze a new way of monitoring for bladder cancer recurrence, using a novel test developed in collaboration with University of Birmingham researchers. 

The cancer biopsy market in France is expected to grow over the forecast period. This growth can be attributed to the strong presence of well-established and emerging product manufacturers, who are expected to adopt continuous organic and inorganic growth strategies to support the market.

The Germany cancer biopsy market is expected to witness substantial growth over the forecast period. The increasing number of companies striving to enter the market and the government-sponsored aid for developing these tests are some of the key factors that can be attributed to the growth of the market.

Asia Pacific Cancer Biopsy Market Trends

The Asia Pacific cancer biopsy industry is expected to witness the fastest CAGR over the projected period, driven by healthcare reforms. Other factors contributing to market growth are an increasing population, improving healthcare infrastructure, and the entry of new players. The Asia Pacific region has a large population and a high prevalence of cancer. According to Global Cancer Statistics, the estimated number of new cases in Asia in 2022 was 10.5 million. Government initiatives, such as free screening for breast cancer, cervical cancer, & lung cancer, and improved collaborations between the government, research institutes, & companies for the distribution & supply of these tests for screening cancers, have increased in the past few years.

The China cancer biopsy market is expected to grow over the forecast period, due to lifestyle changes, dietary habits, and an aging population. Moreover, the demand for liquid biopsy in China is propelled by a large patient pool, government spending on oncology diagnostics, and robust deployment of high-throughput next-generation sequencing platforms.

The cancer biopsy market in Japan is expected to witness growth over the forecast period. This growth can be attributed to the substantial government investments and approvals specifically aimed at reducing incidence.

Latin America Cancer Biopsy Market Trends

The cancer biopsy industry in Latin America is expected to grow during the projected period. This growth of the regional market can be attributed to the increased prevalence of various types of cancer in Latin America. Several surveys by different governments and nonprofit organizations revealed that overall cancer mortality in Latin America is almost twice that of high-income countries.

The Brazil cancer biopsy market is expected to grow over the forecast period. The market has observed high growth in the adoption of cancer biopsy techniques owing to increasing collaborations of key market players and various initiatives being undertaken by various organizations for cancer care.

Middle East & Africa Cancer Biopsy Market Trends

The cancer biopsy industry in the Middle East & Africa is witnessing significant growth opportunities, as most of the market is untapped due to the absence of structured screening programs in underdeveloped African economies has impeded early detection efforts.

The Saudi Arabia cancer biopsy market is expected to grow over the forecast period. This growth can be attributed to the increasing involvement of the government and the rising awareness about the benefits of noninvasive diagnostic procedures.

Key Cancer Biopsy Company Insights

Some of the leading players operating in the market include QIAGEN; Illumina Inc.; and Thermo Fisher Scientific, Inc. These players are involved in developing liquid biopsy technologies. These methods analyze circulating tumor DNA (ctDNA) or other biomarkers in blood samples, providing a less invasive alternative to traditional biopsies. This approach aims to facilitate early detection and ongoing monitoring with minimal discomfort for patients. Moreover, by using these advanced technologies, companies are able to obtain more detailed insights into the genetic mutations and characteristics of tumors.

CureMetrix, Tempus, and Inivata are some of the emerging participants in the cancer biopsy industry. These players are collaborating with other major & local players to gain a competitive edge. These players focus on regional expansion by exploring possibilities to develop innovative diagnostic solutions. This expansion aims to make advanced biopsy technologies more accessible to a broader patient population.

Key Cancer Biopsy Companies

The following key companies have been profiled for this study on the cancer biopsy market.

• QIAGEN

• Illumina, Inc.

• ANGLE plc

• BD (Becton, Dickinson and Company)

• Myriad Genetics, Inc.

• Hologic, Inc.

• Biocept, Inc.

• Thermo Fisher Scientific, Inc.

• Danaher

• F. Hoffmann-La Roche Ltd.

• Lucence Health Inc.

• GRAIL, Inc.

• Guardant Health Inc.

• Exact Sciences Corporation

• Freenome Holdings, Inc.

• Biodesix (Integrated Diagnostics)

• Oncimmune

• Epigenomics AG

• HelioHealth (Laboratory for Advanced Medicine)

• Genesystems, Inc. (Genesys Biolabs)

• Chronix Biomedical, Inc.

• Personal Genome Diagnostics Inc.

• Natera, Inc.

• Personalis Inc.

Recent Developments

• In August 2024, Illumina, Inc. received approval for in vitro diagnostic (IVD) TruSight Oncology (TSO), cancer biomarker tests with its two companion diagnostic indications to rapidly match patients to targeted therapies.

• In June 2024, Guardant Health, Inc. announced the launch of an updated version of the Guardant360 TissueNext test with an expanded identification of genes in tissue samples to 498. This helps enable oncologists to identify treatment strategies and targeted therapies for patients with advanced cancer.

• In May 2024, VESICA HEALTH, INC. announced the launch of the AssureMDX test as an LDT for the diagnosis of bladder cancer.

Global Cancer Biopsy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer biopsy market report based on product, type, application, and region:

To learn more about this report, Download Free Sample Report

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments

  • Kits & Consumables

  • Services

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Tissue Biopsies

    • Needle Biopsies

    • Surgical Biopsies

  • Liquid Biopsies

    • Fine Needle Aspiration (FNA)

    • Core Needle Biopsy (CNB)

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Breast Cancer

  • Colorectal Cancer

  • Cervical Cancers

  • Lung Cancers

  • Prostate Cancers

  • Skin Cancers

  • Blood Cancers

  • Kidney Cancers

  • Liver Cancers

  • Pancreatic Cancers

  • Ovarian Cancers

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The cancer biopsy market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each cancer biopsy segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The Cancer Biopsy Market was estimated using a bottom-up methodology that involved identifying leading market participants and benchmarking their cancer biopsy related product portfolios across instruments, kits and consumables, and diagnostic services. Market assessment was conducted by evaluating product level revenues, procedure volumes, technology adoption rates, patient utilization patterns, and company specific financial performance across key applications. Segment level market values were derived by estimating revenues associated with individual biopsy technologies and validating the findings through adoption trends, market penetration rates, and competitive positioning of major industry participants. The final market size was established through the aggregation of segment revenues and further validated using the market share distribution of key companies operating within the cancer biopsy ecosystem.

To learn more about this report, Download Free Sample Report